Gastroenterology

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses olorinab's efficacy and safety for the treatment of abdominal pain in Crohn's disease.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses a post hoc analysis of biomarkers and clinical outcomes in patients with ulcerative colitis receving etrasimod.

Preston Klassen, MD, head of research and development at Arena Pharamaceuticals, discusses mucosal healing and histologic remission in patients with ulcerative colitis receiving etrasimod.

An analysis of more than 62,000,000 found that prevalence rates of nonalcoholic fatty liver disease were 3 times higher in patients with Crohn's disease.

Investigators presented information on the 9-month interim results of the ABX464-102 phase 2a examining efficacy in UC patients at DDW 2019.

Investigators from Baylor College of Medicine found that dawn to sunset fasting may be a new treatment approach for obesity, metabolic syndrome and NAFLD.

Study from DDW 2019 found that rates of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nonalcoholic cirrhosis was more than double in patients with UC.

A study presented at DDW 2019 found that endoscopic retrieval may help prevent further gastric damage from button battery ingestion.

In a study presented at Digestive Disease Week 2019, results indicated the risk of developing Parkinson's disease was 3 times higher in patients who had appendectomies.

A study presented at DDW 2019 found that women with intrahepatic cholestasis of pregnancy were 5.7 times more likely to have a NAFLD diagnosis

Study presented at DDW 2019 found that walking and resistance training was associated with a lower risk of cirrhosis-related death.

A study presented at DDW 2019 found that endoscopic sleeve gastroplasties found significant and sustainable weight loss among patients 5 years after surgery.

Study presented at DDW 2019 found that transplantation of gut microbes from lean donor could aid weight loss in obese, metabolically healthy recipients.

Teduglutide (Gattex) has been approved as an injection for pediatric patients 1 year of age and older with Short Bowel Syndrome.

Using education, EHR alerts, and increased clinic capacity, investigators increased HCV screening of baby boomers from 10.1% to 34.6%.

Short-course, "post-exposure" direct-acting antivirals enabled successful transplantation of HCV-infected hearts and lungs to uninfected recipients.

Currently, DAAs lack FDA approval for hepatitis C treatment in children under 12 years, but pediatricians call for their approval.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

A new study of 55 million insured young adults in the US found that major depression, type 2 diabetes, and other conditions are becoming more prevalent among them.

A study of DAA treatment of HCV in the US finds high adherence and effectiveness at less cost than when the antivirals were introduced.

Investigators identified reasons veterans might decline or not adhere to HCV treatment and proposed ways to optimize treatment.

A small study in Colorado reported that regular marijuana users require significantly greater amounts of sedatives for endoscopic procedures.

Steatosis was found more often with HCV monoinfection than with HCV/HIV and more commonly detected with imaging than with biopsy.

HCV infection was found to be an independent and significant risk factor for death in patients with chronic kidney disease on maintenance dialysis.

A gene linked to risk for steatosis predicted likelihood of patients with sustained virologic response recovering from decompensated HCV cirrhosis.